Home Tags Mirvetuximab soravtansine-gynx

Tag: mirvetuximab soravtansine-gynx

Immunogen’s Mirvetuximab Soravtansine-gynx Sales Projected to Reach US $ 615 Million...

On November  14, 2022 the US Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic treatment regimens.

World ADC 2023 London – What to Expect

With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...

FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...

X